When was Sciwind Biosciences founded?

Sciwind Biosciences was founded in 2017.

Where is Sciwind Biosciences located?

Sciwind Biosciences is headquartered in Hangzhou, China.

How many employees does Sciwind Biosciences have?

As of Jul 01, 2024, the latest employee count at Sciwind Biosciences is 5.

Is Sciwind Biosciences a funded company?

Sciwind Biosciences is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Sciwind Biosciences rank among its competitors?

Sciwind Biosciences ranks 103rd amongst 394 active competitors, of which 159 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Lexicon Pharmaceuticals, which secured $55.7M in Feb, 2026.

Who are the top competitors of Sciwind Biosciences?

Sciwind Biosciences' top competitors include Sana Biotechnology, Adocia and Lexicon Pharmaceuticals. Among them, Lexicon Pharmaceuticals secured the most recent funding round in February, 2026.

Sciwind Biosciences - 2026 Company Profile & Competitors

Company Details

Developer of therapeutics for metabolic disease treatment. The product candidates include XW003 an injectable GLP-1 analog, XW004 an oral formulation of the GLP-1 peptide, XW014 a small molecule GLP-1 receptor agonist, XW017 is a long-lasting GIP peptide analog, and XW001 is an inhaled formulation of interferon-lambda for the treatment of diabetes, NASH, viral respiratory diseases. and obesity.

Website: sciwindbio.com
Email ID: *****@sciwindbio.com

Key Metrics

Founded Year

2017

Location

Hangzhou, China

Stage

Funding Raised

Ranked

103^rd among 394 active competitors

Employee Count

5 as on Jul 01, 2024

Similar Companies

Sana Biotechnology & 471 more

View Sciwind Biosciences' full profile

Sciwind Biosciences is a funded company.

Sciwind Biosciences' employee count trend

Sciwind Biosciences has 5 employees as of Jul 24. Here is Sciwind Biosciences's employee count trend over the years:

Employee count trend for Sciwind Biosciences

Uncover Sciwind Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Sciwind Biosciences include Sana Biotechnology, Adocia and Lexicon Pharmaceuticals. Here is the list of Top 10 competitors of Sciwind Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
2nd	Adocia 2005, Lyon (France), Public	Developer of therapeutics for the treatment of diabetes and obesity	$26M	Stifel, Smalt Capital & 6 others	69/100
3rd	Lexicon Pharmaceuticals 1995, The Woodlands (United States), Public	Developer of small molecule drugs for diffrent health diseases	-	Bay City Capital, BCM Technologies & 3 others	68/100
4th	Rezolute 2012, Denver (United States), Public	Developing transformative therapies for rare diseases, focusing on hyperinsulinism (HI)	-	BVF Partners, Citadel & 8 others	67/100
5th	Zucara Therapeutics 2015, Vancouver (Canada), Series B	Developing a long-term therapeutic approach to prevent hypoglycemia in patients with diabetes	$50.8M	TIAP, Cdrd.ca & 14 others	66/100
6th	Think Bioscience 2019, Boulder (United States), Series A	Provider of synthetic biology platform to develop small-molecule therapeutics	$26M	Innovation Endeavors, Janus Henderson Investors ... & 12 others	65/100
7th	Cellino 2017, Cambridge (United States), Series A	Developer of autologous cell therapies	$125M	8VC, Khosla Ventures & 7 others	65/100
8th	Kailera 2024, Waltham (United States), Series B	Developer of therapies for treating obesity and related conditions	$1B	Bain Capital Life Sciences, RTW Investments ... & 12 others	63/100
9th	Veralox Therapeutics 2017, Frederick (United States), Series B	Developer of small molecules for treating thrombosis and diabetes pathologies	$47.5M	Sanofi Ventures, T1D Fund & 13 others	62/100
10th	Kriya Therapeutics 2012, Redwood City (United States), Series D	Developer of therapeutic solutions for the treatment of diabetes	$938M	Patient Square Capital, Foresite Capital ... & 16 others	62/100
103rd	Sciwind Biosciences 2017, Hangzhou (China), Funding Raised	Developer of therapeutics for metabolic disease treatment	-	-	42/100